Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV001 in keloid recurrence
NCT04827875Phase 1Completed
- Sponsor
- AiViva BioPharma
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of axitinib in keloid and scar (2 arms), sponsored by AiViva BioPharma. Primary endpoint: Adverse events at 365 days. Started Jun 2021; status: completed.
02
Drugs
axitinib
03
Conditions
keloidscar
Beyond the preview
Go deeper on NCT04827875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827875.